New Haven Pharmaceuticals

11 articles about New Haven Pharmaceuticals

• New Haven Pharmaceuticals Presents Survey Results That Showed High Risk Cardiovascular Patients Believed That There Are Generally Greater Benefits Associated With Prescription Versus OTC Medications

  3/8/2016

• New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA Is Well Tolerated And Delivers Sustained 24-Hour Antiplatelet Control

  3/1/2016

• New Haven Pharmaceuticals Announces Availability of DURLAZA, First And Only Once-Daily 24-Hour Aspirin

  1/8/2016

• New Haven Pharmaceuticals President Named 2015 Entrepreneur Of The Year By Connecticut United For Research Excellence (CURE)

  12/16/2015

• New Haven Pharmaceuticals: Study Shows DURLAZA (aspirin) Extended-Release Capsules Delivers Sustained Antiplatelet Effects For Full 24 Hours

  11/10/2015

• New Haven Pharmaceuticals To Share DURLAZA (aspirin) Extended-Release Capsules Study Data At American Heart Association Scientific Sessions Fall Event

  11/2/2015

• New Haven Pharmaceuticals Receives FDA Approval For DURLAZA (Aspirin) Extended Release Capsules For Secondary Prevention Of Stroke And Acute Cardiac Events

  9/8/2015

• New Haven Pharmaceuticals Expands Management Team With Two Senior-Level Appointments

  10/8/2014

• New Haven Pharmaceuticals Appoints Larry Dillaha, M.D. As Executive Vice President Operations

  4/2/2014

• Connecticut Innovations Makes Follow-On Investment In New Haven Pharmaceuticals

  1/30/2014

• New Haven Pharmaceuticals Gets $6 Million, Prepares for Approval

  10/30/2012